Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?

Moderna (MRNA) stock broke out for the first time in over a year on May 2 after the biotech company notched a big quarterly beat on the back of its Covid vaccine.X During the quarter, the Covid vaccine called Spikevax brought in $167 million in sales, well above forecasts for $93 million, according to FactSet. Losses also came in better than expected at $3.07 per share, though reversed from a year-earlier gain.Notably, Moderna kept its outlook for the year.Later this month, the Food and Drug Administration ...